Literature DB >> 18589049

Perspectives on "chronic Lyme disease".

Phillip J Baker1.   

Abstract

There is much controversy about the treatment of Lyme disease with respect to 2 poorly defined entities: "chronic Lyme disease" and "posttreatment Lyme disease syndrome." In the absence of direct evidence that these conditions are the result of a persistent infection, some mistakenly advocate extended antibiotic therapy (>/=6 months), which can do great harm and has resulted in at least 1 death. The purpose of this brief report is to review what is known from clinical research about these conditions to assist both practicing physicians and lawmakers in making sound and safe decisions with respect to treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589049     DOI: 10.1016/j.amjmed.2008.02.013

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease".

Authors:  Afton L Hassett; Diane C Radvanski; Steven Buyske; Shantal V Savage; Leonard H Sigal
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

2.  Epitope-Specific Evolution of Human B Cell Responses to Borrelia burgdorferi VlsE Protein from Early to Late Stages of Lyme Disease.

Authors:  Elzbieta Jacek; Kevin S Tang; Lars Komorowski; Mary Ajamian; Christian Probst; Brian Stevenson; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

3.  Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms.

Authors:  Abhishek Chandra; Gary P Wormser; Mark S Klempner; Richard P Trevino; Mary K Crow; Norman Latov; Armin Alaedini
Journal:  Brain Behav Immun       Date:  2010-03-18       Impact factor: 7.217

4.  Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome.

Authors:  Abhishek Chandra; Norman Latov; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  Clin Immunol       Date:  2011-07-02       Impact factor: 3.969

Review 5.  γδ T Cells and dendritic cells in refractory Lyme arthritis.

Authors:  Ali Divan; Ralph C Budd; Richard P Tobin; M Karen Newell-Rogers
Journal:  J Leukoc Biol       Date:  2015-01-20       Impact factor: 4.962

6.  Implications of gender in chronic Lyme disease.

Authors:  Gary P Wormser; Eugene D Shapiro
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

7.  Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome.

Authors:  Kevin S Tang; Mark S Klempner; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  Clin Infect Dis       Date:  2015-07-28       Impact factor: 9.079

Review 8.  Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review.

Authors:  R Dersch; H Sommer; S Rauer; J J Meerpohl
Journal:  J Neurol       Date:  2015-10-12       Impact factor: 4.849

Review 9.  Treatment of Lyme borreliosis.

Authors:  Hermann J Girschick; Henner Morbach; Dennis Tappe
Journal:  Arthritis Res Ther       Date:  2009-12-17       Impact factor: 5.156

10.  Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study.

Authors:  Ather Ali; Lawrence Vitulano; Robert Lee; Theresa R Weiss; Eve R Colson
Journal:  BMC Fam Pract       Date:  2014-05-01       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.